XML 17 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
The Company and Summary of Significant Accounting Policies (Details) (USD $)
In Thousands, unless otherwise specified
 1 Months Ended 12 Months Ended 144 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended
Mar. 04, 2013
Dec. 31, 2013
Segment
Patients
Dec. 31, 2012
Dec. 31, 2013
Feb. 07, 2014
Subsequent Event
Feb. 28, 2014
Two Zero One Four Equity Financings
Subsequent Event
Registered Direct Offering
Dec. 31, 2013
Phase 3 heart failure (HF) trial of Gencaro
Patients
Company Development Stage and Basis of Presentation (Textual) [Abstract]              
Number of patients             2,708
Number of patients company trial to enroll   200         420
Number of years to complete the study   2 years 6 months          
Loss from operations   $ (6,940) $ (4,319) $ (106,083)      
Cash flows from operations   (5,288) (4,078) (102,709)      
Fund raised through sale of convertible preferred and common stock   19,300   10,841      
Proceeds from the issuance of common stock   $ 1,741 $ 1,528 $ 15,850 $ 7,900 $ 7,900  
Reverse stock split 1-for-6 reverse split 1-for-20 reverse stock split          
Merger conversion ratio   0.16698070          
Number of segments   1          
Cash and cash equivalents maturity period   90 days or less